/
/
Beginning Myeloma Treatments Impact the Achievement of MRD-negative Goal
Beginning Myeloma Treatments Impact the Achievement of MRD-negative Goal image
Beginning Myeloma Treatments Impact the Achievement of MRD-negative Goal
Posted Aug 07, 2017

BY PAUL KLEUTGHEN The current issue of the Journal of Clinical Oncology reports more interesting research that, again, confirms the importance of achieving minimal residual disease (MRD) negative status in multiple myeloma treatment. This is an important topic that has already been presented earlier on this site. The focal point of the article was to point to the positive difference in progression free survival and overall survival for patients who achieved MRD-negative status. Of interest to note, however, is the embedded report of how different induction regimens impact the achievement of MRD-negative status. The authors report that 50% (out of + 600 patients studied) of those patients who underwent an induction regimen of VDT (Velcade, thalidomide, dexamethasone) followed by stem cell transplant achieved MRD-negative status. This compares to only 11 % for patients who were given an ‘older’ induction regimen named VBMCP/VBAD (vincristine, carmustine, cyclophosphamide, prednisone/vincristine, carmustine, doxorubicin and dexamethasone). There is no need to discuss these two regimens here, or for that matter, other induction regimens that are used in clinical practice these days. The point that we would like to make is that for the newly diagnosed patient is it well worth to pop the question “And what induction regimen is expected to give me the best chance to get me to MRD-negative status post-transplant ?” Let your myeloma specialist guide you through the options and their experience with outcomes so you can make an informed decision.

The author Paul Kleutghen

about the author
Paul Kleutghen

I am a patient diagnosed in 2014 with primary plasma cell leukemia (pPCL), a rare and aggressive variant of multiple myeloma and have been very fortunate to find successful treatment at the division of Cellular Therapy at the Duke University Cancer Institute. My wife, Vicki, and I have two adult children and two grandsons who are the ‘lights of our lives’. Successful treatment has allowed Vicki and I to do what we love best : traveling the world, albeit it with some extra precautions to keep infections away. My career in the pharmaceutical industry has given me insights that I am currently putting to use as an advocate to lower drug pricing, especially prices for anti-cancer drugs. I am a firm believer that staying mentally active, physically fit, compliant to our treatment regimen and taking an active interest in our disease are keys to successful treatment outcomes.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811